CD19 and systemic lupus erythematosus: The rapid decline in anti-dsDNA antibody levels observed in SLE patients undergoing anti-CD19 CAR T-cell therapy suggests that CD19+ plasmablasts and CD19+ plasma cells are the primary sources of these autoantibodies.